Hosseinimehr Seyed Jalal
Department of Radiopharmacy, Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran;
Future Oncol. 2014 Dec;10(15):2381-90. doi: 10.2217/fon.14.177.
Angiotensin II receptor antagonists inhibit various signaling pathways involved in the regulation of inflammation, apoptosis and angiogenesis. Radiation-induced activation of a proinflammatory cytokine network has been shown to mediate normal tissue injury induced by ionizing radiation in cancer patients, resulting in serious side effects. Hence, not only do angiotensin II receptor antagonists block inflammatory signaling both in cancer cells and in normal cells, but they are also effective in the treatment of cancer by inhibiting tumor progression, vascularization and metastasis. This review addresses the role of angiotensin II inhibitors in cancer therapy, and their potential to increase therapeutical index by protecting normal cells and sensitizing tumor cells to radiotherapy.
血管紧张素II受体拮抗剂可抑制参与炎症、细胞凋亡和血管生成调节的各种信号通路。辐射诱导的促炎细胞因子网络激活已被证明可介导癌症患者电离辐射引起的正常组织损伤，从而导致严重的副作用。因此，血管紧张素II受体拮抗剂不仅能阻断癌细胞和正常细胞中的炎症信号，还能通过抑制肿瘤进展、血管生成和转移有效治疗癌症。本文综述了血管紧张素II抑制剂在癌症治疗中的作用，以及它们通过保护正常细胞和使肿瘤细胞对放疗敏感来提高治疗指数的潜力。
